» Articles » PMID: 38276984

Assessing Adverse Pregnancy Outcomes in Women with Uncontrolled Asthma Vs. Mild Asthma: a Retrospective Comparative Analysis

Overview
Date 2024 Jan 26
PMID 38276984
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The aim of this study was to evaluate perinatal outcomes between the uncontrolled asthma group and the mild asthma group and to reveal the relationship between disease severity and adverse maternal-fetal outcomes in this study.

Methods: This retrospective cohort study analyzed 180 pregnant women diagnosed with asthma, hospitalized, and delivered at our center between September 1, 2019, and December 1, 2021. We compared two groups: 160 with mild asthma and 20 with uncontrolled asthma. Data encompassed maternal characteristics, obstetrical complications, medication use, emergency department admissions for exacerbations, smoking status, and neonatal outcomes.

Results: In the uncontrolled asthma group, hospitalization rates, use of inhaled short-acting β-agonist (SABA), and systemic corticosteroids were significantly higher compared to the mild asthma group (p < 0.01). Maternal and fetal complications were more prevalent in the uncontrolled group, including asthma exacerbations (45% vs. 1.2%), anemia (10% vs. 4.4%), prematurity (25% vs. 9.6%), and intrauterine fetal demise (IUFD) (10% vs. 0.6%). Neonatal outcomes in the uncontrolled group showed higher rates of admission to the neonatal intensive care unit (NICU) (50% vs. 25%), respiratory distress syndrome (RDS) (30% vs. 14%), and intraventricular hemorrhage (IVH) (5% vs. 0%) compared to the mild asthma group.

Conclusion: Uncontrolled asthma during pregnancy is associated with higher adverse maternal-fetal and neonatal outcomes compared to mild asthma.

References
1.
Murphy V, Jensen M, Gibson P . Exacerbations of asthma following step-up and step-down inhaled corticosteroid and long acting beta agonist therapy in the managing asthma in pregnancy study. J Asthma. 2020; 59(2):362-369. DOI: 10.1080/02770903.2020.1847934. View

2.
Vieira A, Pite H, Morais-Almeida M . Asthma and pregnancy in the 2020 decade: still a matter of concern. J Matern Fetal Neonatal Med. 2021; 35(25):6498-6504. DOI: 10.1080/14767058.2021.1916462. View

3.
Xu Z, Doust J, Wilson L, Dobson A, Dharmage S, Mishra G . Asthma severity and impact on perinatal outcomes: an updated systematic review and meta-analysis. BJOG. 2021; 129(3):367-377. DOI: 10.1111/1471-0528.16968. View

4.
McLaughlin K, Jensen M, Foureur M, Murphy V . Are pregnant women with asthma receiving guideline-recommended antenatal asthma management? A survey of pregnant women receiving usual care in Australia. Women Birth. 2022; 36(1):108-116. DOI: 10.1016/j.wombi.2022.03.008. View

5.
Beau A, Didier A, Hurault-Delarue C, Montastruc J, Lacroix I, Damase-Michel C . Prescription of asthma medications before and during pregnancy in France: An observational drug study using the EFEMERIS database. J Asthma. 2016; 54(3):258-264. DOI: 10.1080/02770903.2016.1214731. View